logo risk new2

Partners

The consortium of the RISK-IR project brings together expertise from 13 research groups of 10 institutions from 7 European countries.

6

  Click on their name for further information and on their logo to reach the site of each insitution.

Helmholtz Zentrum München (HMGU), Germany.

logo HMGUHelmholtz Zentrum München is a research institution of the Federal Republic of Germany and the Free State of Bavaria.

It is divided into 33 research institutes and independent research units, which are interlinked and cooperate on various topics and in various research programs. The centre has diverse technology platforms which function as central service units. To ensure rapid and efficient transfer of findings from basic research into medical applications, scientists of Helmholtz Zentrum München work closely in translational centres and clinical cooperation groups together with medical partners in the universities and hospitals in Munich.

The research mission of Helmholtz Zentrum München is to increase understanding of disease mechanisms which affect human beings and essential parts of their environment. The Centre is developing the fundamental principles for the medicine of the future and for a personalized medicine focused on addressing the causes of disease. 

The Institute for Radiation Biology

The Institute of Radiation Biology (ISB) focuses on studying the impacts of ionising radiation on health. Within the Department of Radiation Sciences we contribute to the programmes on medical applications and personalized medicine. Clearly, radiation sciences are a core activity in any study of the health effects of the natural and man-made environment, and as such fall within the scope of the broader Helmholtz Mission of the HMGU. We are in particular concerned with studying the mechanisms responsible for the development of long-term health effects of exposure to radiation and on improving the effectiveness of radiation therapy in oncology. We focus here on understanding the biology behind the development of late effects of radiation on the cardiovascular system and cancer, understanding the role of cellular stress responses, and elucidating the mechanisms of individual susceptibility.

We collaborate with eight other institutes in Neuherberg, as well as with the Munich Universities, the Federal Office of Radiation Protection, and the Medical Academy of the federal army. Nationally we are partners in the BMBF-KVSF network and internationally we participate in four EURATOM research projects (STORE, GENRISK-T, CARDIORISK, DoReMi). Our Institute holds a patent application for a biological dosimetry method for radiological protection and radiotherapy purposes. We conduct translational clinical research in conjunction with two Helmholtz Clinical Cooperation Groups, as well as with the clinical radiation therapy departments of the TUM and LMU.

Michael Rosemann, PhD is Principal investigator and group leader for “Radiation Carcinogenesis”. We study the inherent differences in susceptibility of different inbred mouse strains to radiation-induced osteosarcoma, thyroid cancer and leukaemia. We have established that functional differences in the retinoblastoma gene (Rb1) play a major role in determining susceptibility to osteosarcoma. We are investigating how Rb1 actually modifies the radiation response by focussing on the maintenance of genome integrity during radiation-induced carcinogenesis. M.Rosemann supervised 10 MSc and 6 PhD projects at the institute. He is organiser and coordinator of a European MSc course “Radiobiology” (together with UCL London) and of DoReMi training courses on “Molecular Radiation Carcinogenesis”, “Radiation Epidemiology and Radioecology”. Michael has also been coordinator and/or PI of several German and European research projects (EU IMRAD, EURATOM RiskRad, EURATOM Generisk-T, EURATOM GENERAD).

 

Member Login

Members please login and navigate to the 'Library' option that will appear above to find Forms, Meeting Minutes and Reports.